Clinical Trials Sponsored by Grupo Español Multidisciplinar de Melanoma

Total 185 results

Grupo Español Multidisciplinar de Melanoma

Recruiting

Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain (GEM-1801)

Advanced Cancer | Melanoma Stage Iv | Melanoma Stage Iii

Spain
Grupo Español Multidisciplinar de Melanoma

Completed

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma (BRAFV600)

Stage IV Skin Melanoma

Spain
Grupo Español Multidisciplinar de Melanoma
GlaxoSmithKline

Completed

Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain (DEIS)

Malignant Melanoma Stage IV | Malignant Melanoma Stage IIIc

Spain
Grupo Español Multidisciplinar de Melanoma
MFAR

Withdrawn

Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma (CEDUVEAL-M)

Metastatic Cancer | Uveal Melanoma

Spain
Grupo Español Multidisciplinar de Melanoma
Bristol-Myers Squibb

Completed

GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (GRAY-B)

Melanoma | Brain Metastases

Spain
Grupo Español Multidisciplinar de Melanoma
Bristol-Myers Squibb

Completed

Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma (GEM1402)

Uveal Melanoma

Spain
Grupo Español Multidisciplinar de Melanoma
Mirati Therapeutics Inc.; BeiGene

Active, not recruiting

Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (SITISVEAL)

Uveal Melanoma

Spain
Grupo Español Multidisciplinar de Melanoma
Pierre Fabre Medicament; MFAR

Active, not recruiting

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)

Metastatic Melanoma | Brain Metastases

Spain
Grupo Español Multidisciplinar de Melanoma
Roche Farma, S.A; Pivotal S.L.

Completed

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients (AVEVAC)

Colorectal Carcinoma

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Unknown

Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. (BECOX)

Metastatic Colorectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Recruiting

GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer. (REVEAL)

Patients With Locally Advanced Rectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Active, not recruiting

Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer

Metastatic Colon Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer (GEMCAD1003)

Pancreatic Adenocarcinoma

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma

Pancreatic Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Recruiting

Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL)

Colorectal Cancer Metastatic | Liver Metastasis Colon Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (POSIBA)

Colorectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer (AVAMET)

Colorectal Cancer | Hepatic Metastasis

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Merk Sharp & Dohme España S.A.

Recruiting

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA)

Metastatic Colorectal Cancer

Spain
Grupo Español de Rehabilitación Multimodal

Active, not recruiting

POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol

Colorectal Surgery | Enhanced Recovery After Surgery | Critical Pathways | Chemotherapy, Adjuvant | Retrospective Studies

Spain
Grupo Español de Rehabilitación Multimodal

Unknown

Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol in Gastric Surgery for Cancer (POWER4)

Postoperative Complications | Gastric Cancer | Perioperative Care

Spain
Grupo Español de Rehabilitación Multimodal

Unknown

Validity of Aortic Pulse Wave Velocity in Predicting the 6- Minute Walking Test Before Major Non-cardiac Surgery (6WAVE)

Surgery | Perioperative/Postoperative Complications | Exercise Tolerance

Spain
Grupo Español de Rehabilitación Multimodal

Unknown

Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol (POWER2) (POWER2)

Arthroplasty, Replacement, Knee | Arthroplasty, Replacement, Hip

Spain
Grupo Español de Síndromes Mielodisplásicos

Completed

Spanish Registry of Erythropoietic Stimulating Agents Study (SPRESAS)

Myelodysplastic Syndrome
Grupo Español de Rehabilitación Multimodal

Completed

Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol (POWER)

Postoperative Complications | Colorectal Surgery | Perioperative Care | Critical Pathways

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Pivotal S.L.

Completed

Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer (RIA)

Rectal Cancer
Grupo Español de Rehabilitación Multimodal
REDGERM; Sociedad Española de Cirugía de la Obesidad

Unknown

Postoperative Outcomes Within an Enhanced Recovery After Bariatric Surgery Protocol (POWER3)

Postoperative Complications | Bariatric Surgery Candidate | Perioperative Care

Spain
Grupo Espanol de Tumores Neuroendocrinos

Recruiting

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor (NUTRIGETNE)

Gastroenteropancreatic Neuroendocrine Tumor

Spain
Grupo Espanol de Tumores Neuroendocrinos

Recruiting

GETNE Registration of Thyroid Cancer

Thyroid Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos

Active, not recruiting

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Neuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

Spain
Grupo Español de Investigación en Neurooncología

Completed

Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients

Glioblastoma

Spain
Grupo Español de Investigación en Neurooncología

Unknown

Metronomic Temozolamide in Patients With Recurrent Glioblastoma

Glioblastoma
Grupo Espanol de Tumores Neuroendocrinos

Completed

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (DUNE)

Neuroendocrine Tumors | Neuroendocrine Neoplasm of Lung

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria (CRIPNET)

Pancreatic Neuroendocrine Tumors

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) (PALBONET)

Pancreatic Neuroendocrine Cancer

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET (EVERLAR)

Gastrointestinal Neoplasms

Spain
Grupo Español de Investigación en Neurooncología

Completed

Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma (GEINOGLAS)

Glioblastoma

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Hoffmann-La Roche

Recruiting

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS)

Squamous Cell Carcinoma of the Anal Canal

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Completed

Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery (PIER)

Rectal Cancer

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Completed

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (OPALO)

Neoplasm Metastasis | Colorectal Neoplasms | Colorectal Cancer Metastatic | Colorectal Carcinoma

Spain
Grupo Espanol de Tumores Neuroendocrinos

Completed

Pazopanib as Single Agent in Advanced NETs

Advanced/Metastatic Neuroendocrine Tumors

Spain
Grupo Español de Investigación en Neurooncología

Completed

Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.

Glioblastoma

Spain
Grupo Español de Investigación en Neurooncología

Completed

Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma

Glioblastomas

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Active, not recruiting

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (BEYOND)

Colorectal Cancer Metastatic

Spain
Grupo Español de Investigación en Cáncer de Ovario

Recruiting

DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer (DORA)

Endometrial Cancer

Spain
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma Multiforme (Grade IV) of Cerebellum

Spain
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Glioblastoma | Brain Tumor, Recurrent

Spain
Grupo Espanol de Investigacion en Sarcomas

Recruiting

Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS)

Soft Tissue Sarcoma | Bone Tumors | Small Round-cell Sarcomas

Spain
Grupo Espanol de Investigacion en Sarcomas

Recruiting

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc)

Soft Tissue Sarcoma | Bone Sarcoma

Spain, United Kingdom, Italy

Clinical Trials Sponsored by Grupo Español Multidisciplinar de Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations